Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierViatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $3.52BThe company’s own SEC segment disclosure.
- Brands$1.07B30%
- Generics$951.8M27%
- Lipitor$462.0M13%
- Norvasc$210.0M6%
- Lyrica$120.6M3%
- Epi Pen Auto Injectors$101.1M3%
- Other (10)$601.9M17%
Viatris (VTRS) reported revenue of $3.76B in Q2 2026 (quarter ended June 30, 2026), up 4.9% from the same quarter a year earlier. That came with a gross margin of 39% and net loss of $119M. For the full year FY2025, revenue was $14.3B (−3.0% year on year) and net income −$3.51B. Its largest product in 2026-Q1 was Brands at $1.07B, 30% of the disclosed total, just ahead of Generics at 27%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #7 of 28 by Smart Score